ABSTRACT
Endometrial stromal sarcoma (ESS) formerly classified as low-grade endometrial stromal sarcoma is a rare uterine malignancy with a good prognosis despite a tendency to recur. Primary surgical management for ESS includes total abdominal hysterectomy and bilateral salpingo-oophorectomy. Patients with ESS have long disease-free survival rates when treated with primary surgical therapy, but nearly fifty percent of these patients will recur. We present the case of a patient with recurrent ESS who had an excellent response to combined therapy with megestrol and leuprolide.
Subject(s)
Bronchial Neoplasms/epidemiology , Lung Neoplasms/epidemiology , Smoking/adverse effects , Women's Health , Bronchial Neoplasms/etiology , Bronchial Neoplasms/history , Female , History, 15th Century , History, 16th Century , History, 17th Century , History, 18th Century , History, 19th Century , History, 20th Century , Humans , Lung Neoplasms/etiology , Lung Neoplasms/history , Smoking/historySubject(s)
Genital Neoplasms, Female/radiotherapy , Brachytherapy , Breast Neoplasms/radiotherapy , Dysgerminoma/radiotherapy , Endometrial Neoplasms/radiotherapy , Female , Health Physics , Humans , Ovarian Neoplasms/radiotherapy , Pregnancy , Radiation Tolerance , Radiobiology , Radiotherapy Dosage , Trophoblastic Neoplasms/radiotherapy , Uterine Cervical Neoplasms/radiotherapy , Uterine Neoplasms/radiotherapy , Vaginal Neoplasms/radiotherapy , Vulvar Neoplasms/radiotherapyABSTRACT
Primary prevention of uterine cervix cancer spans the gamut of human papillomavirus vaccine development, dietary adjustment, chemoprevention, and risk reduction. Lifestyle and social behaviors impact on risk for cervical cancer. Before examining the growing body of molecular evidence, animal studies, and phase I clinical trials that suggest that a virus-based vaccine for cervical cancer may soon become a reality, one must reflect on what has gone before in the vaccine-based battle with viral disease.
